Quince Therapeutics, Inc.
QNCX
$1.63
$0.021.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.05M | -15.03M | -12.46M | -5.49M | -27.73M |
| Total Depreciation and Amortization | 35.00K | 32.00K | 16.00K | 86.00K | 44.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.47M | 3.35M | 3.00M | -1.70M | 20.37M |
| Change in Net Operating Assets | -1.87M | 2.05M | 1.90M | -152.00K | -1.42M |
| Cash from Operations | -11.42M | -9.60M | -7.55M | -7.26M | -8.74M |
| Capital Expenditure | -126.00K | -148.00K | -133.00K | -46.00K | -39.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.17M | 11.05M | 11.00M | 7.15M | -4.94M |
| Cash from Investing | 6.04M | 10.90M | 10.87M | 7.11M | -4.98M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 14.41M | 87.00K | 0.00 | 0.00 | 35.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | -5.00M | -- |
| Cash from Financing | 14.41M | 87.00K | 0.00 | -5.00M | 35.00K |
| Foreign Exchange rate Adjustments | 19.00K | 175.00K | 222.00K | -60.00K | -241.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.06M | 1.56M | 3.54M | -5.22M | -13.92M |